source
- Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trialKallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…
- Boehringer's obesity drug shows up to 9.8% weight loss in diabetes patients but lags behind competitorsBoehringer Ingelheim presented data at the European Association for the Study of Diabetes (EASD) meeting in Milan, showing its lead obesity candidate achieved up to 9.8% weight reduction in a late-…